Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

The FDA is proposing a new regulatory pathway to accelerate First-in-Human clinical trials by allowing non-animal, new approach methods to substitute for traditional toxicology requirements. While this initiative aims to reduce development time and costs, it faces significant hurdles, including the need for congressional authorization and extensive scientific validation. Current international models, such as those in Australia and China, achieve speed through streamlined processes rather than fundamental changes to evidentiary standards. Simultaneously, the biopharma industry is experiencing a surge in deal-making, with major acquisitions like Gilead’s $3.15 billion purchase of Tubulus and Neurocrine’s investment in Prader-Willi syndrome treatments. Furthermore, large-scale capital injections from firms like Blackstone, which recently closed a $6.3 billion fund, and JATO, which raised a billion-euro fund, are increasingly supporting late-stage clinical development and risk-sharing collaborations to bridge translational gaps in the biotech sector.